Posted by Michael Wonder on 24 Oct 2025
Apotex receives Health Canada approval for Loqtorzi - the first and only immuno-therapy for recurrent unresectable or metastatic nasopharyngeal cancer
23 October 2025 - Apotex today announced that Health Canada has granted a notice of compliance for Loqtorzi (toripalimab) for the treatment of nasopharyngeal carcinoma, an ultra-rare and aggressive cancer.
Loqtorzi is the first and only Health Canada approved immuno-therapy for patients with recurrent unresectable or metastatic nasopharyngeal cancer, offering an effective new immuno-therapy option to patients facing this challenging malignancy.
